Skip to main content

Market Overview

argenx: Q4 Earnings Insights



Shares of argenx (NASDAQ:ARGX) fell 3.2% in pre-market trading after the company reported Q4 results.

Quarterly Results

Earnings per share were down 60.08% year over year to ($4.21), which missed the estimate of ($3.19).

Revenue of $7,587,000 declined by 60.98% year over year, which missed the estimate of $19,310,000.

Looking Ahead

argenx hasn't issued any earnings guidance for the time being.

argenx hasn't issued any revenue guidance for the time being.

Details Of The Call

Date: Mar 04, 2021

Time: 08:30 AM

ET Webcast URL:

Price Action

52-week high: $382.15

Company's 52-week low was at $103.75

Price action over last quarter: Up 22.20%

Company Profile

argenx SE is a clinical stage biotechnology company. It is engaged in the business of developing a pipeline of differentiated antibody-based therapies for the treatment of severe autoimmune diseases and cancer. Its product pipeline includes product candidates such as ARGX-111, ARGX-109, ARGX-115, ARGX-112, and others. The company operates in the Netherlands, Germany, Denmark, Belgium, Switzerland, the United States, and Luxembourg. It derives the majority of its revenues from Switzerland.


Related Articles (ARGX)

View Comments and Join the Discussion!

Posted-In: BZI-RecapsEarnings News

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at